We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment, and teamwork, and so can you. We are currently recruiting for an Aseptic Filling Biotechnologist. In this role, you will be responsible for performing functions related to production and GMP manufacturing operations. You will be responsible for adhering to all QMS policies and procedures, cGMP and safety standards. Oxford Biomedica’s Manufacturing Team is responsible for the production and aseptic fill and finish of vectors, for our clients and partners, to Good Manufacturing Practice (GMP) standard. Your responsibilities in this role would be: • Contributing to housekeeping including cleaning, sanitisation and sterilisation of equipment and components • Performing all manufacturing operations including but not limited to component transfer and preparation, equipment and area preparation, • Maintaining QMS documentation, keeping accurate records, following instructions and complying with company policies • Ensuring compliance with Quality policies, SOPs and Health and Safety procedures • Supporting troubleshooting activities and assisting with continuous improvement initiatives • Undertaking any other appropriate roles and responsibilities that reasonably fall within the role holder’s skills and experience as requested • Providing OXB’s routine manufacture of vector product • Being accountable as part of a team of aseptic filling biotechnologists working on shift pattern to successfully fill, inspect, label and pack Vector Product • Investigating quality incidents, deviations and improving procedures We are looking for: • Cleanroom experience or good understanding of GMP and Good Clinical Practice preferred • Excellent interpersonal skills, organised and enthusiastic and comfortable working autonomously or in a team environment • Willingness to follow GMP PPE requirements during the working shift • Excellent attention to detail • BSc Life Sciences or equivalent or alternatively some previous experience of working within a biological or chemical GMP manufacturing environment • Excellent writing skills and computer literacy • Flexibility to work shift patterns inclusive of weekends About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: • Highly competitive total reward packages • Wellbeing programmes • Development opportunities • Welcoming, friendly, supportive colleagues • A diverse and inclusive working environment • Our values are: Responsible, Responsive, Resilient, Respect • State of the art laboratory and manufacturing facilities We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you. Collaborate. Contribute. Change lives Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.